Seer (SEER) Stock: Buy, Sell, or Hold?
SEER - Seer, Inc. Class A Common Stock
$1.95
0.02 (1.04%)
▲
5d:
+0.52%
30d:
-8.88%
90d:
+14.71%
BUY
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When SEER Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SEER shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SEER shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SEER is currently trading at $1.95, which is considered oversold relative to its 30-day fair value range of $1.95 to $2.13.
Technical Outlook: Technically, SEER is in a uptrend. The price is currently testing key support at $1.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SEER scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Implied Volatility is high (93th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $4.00 (+105.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SEER is in a uptrend. The price is currently testing key support at $1.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SEER scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Implied Volatility is high (93th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $4.00 (+105.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.95 -
$2.13
Company Quality Score
64/100
(BUY)
Options IV Signal
93th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
75.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 93th percentile)
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 105.1% below Wall St target ($4.00)
- BULLISH: Bottoming setup score 66/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.95 -
$2.13
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.64
(33.1%)
Support & Resistance Levels
Support Level
$1.93
Resistance Level
$2.02
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.91
Wall Street Target
$4.00
(+105.1%)
Revenue Growth (YoY)
-23.4%
Share & Embed Analysis
Last updated: September 12, 2026 12:47 AM ET
Data refreshes hourly during market hours. Next update: 1:47 AM
Data refreshes hourly during market hours. Next update: 1:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SEER showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
